Chemomab’s OLE study of nebokitug in PSC patients confirmed safety and showed improvements in liver stiffness, fibrosis biomarkers, and cholestasis markers.
Chemomab Therapeutics’ Touts Positive Data From Experimental Drug For Chronic Liver Disease

Where Today's News Shapes Tomorrow